ALK Inhibitor Alectinib Shows DFS Benefit in Early NSCLC ...Middle East

Medscape - News
Interim findings from the ALINA trial show improved DFS with alectinib in the adjuvant setting vs chemotherapy in resected stage IB-IIIA NSCLC. But will early DFS results extend to overall survival? Medscape Medical News

Hence then, the article about alk inhibitor alectinib shows dfs benefit in early nsclc was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( ALK Inhibitor Alectinib Shows DFS Benefit in Early NSCLC )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News